Abstract 371P
Background
Head and neck cancers (HNCs) are a challenging disease to treat due to their anatomical complexity and high propensity for locoregional recurrence. Radiation therapy is a crucial component of treatment approach for HNCs. However, assessing the response to therapy can be difficult, particularly in the early post-treatment period. Positron emission tomography (PET) with the glucose analogue [18F] fluorodeoxyglucose (FDG) has shown promising results in the assessment of treatment response in HNCs. Therefore, this systematic review is written to evaluate the role of FDG-PET/CT in the assessment of response to radiotherapy in HNCs.
Methods
A comprehensive search of electronic databases was conducted, including EMBASE, Scopus, Pubmed, PMC, and Science Direct from inception to April 2023. Studies were included if they reported on the use of FDG-PET/CT for assessing treatment response in HNCs treated with radiation therapy. Quality assessment using Newcastle-Ottawa Scale and data extraction were performed independently by three reviewers.
Results
16 studies reporting on a total of 348 patients were included in this analysis. The data assessed in the included studies were diverse, including the evaluation of the diagnostic performance of FDG-PET/CT, the comparison with conventional imaging techniques, the ability to avoid neck dissections, or assessed which patient population would derive most benefit from post-treatment FDG-PET/CT scan. Despite their diversity, almost all studies have showed that FDG-PET/CT scan is a reliable method to evaluate residual or recurrent tumour within 6 months post-(chemo)radiation therapy with pooled sensitivity of 84% and pooled specificity of 90%. There was a moderate risk of bias due to selection bias. Also, confirmation of positive nodal disease at the time of diagnosis and prior to therapy is an important shortcoming in most included studies.
Conclusions
FDG-PET/CT within 6 months after (chemo)radiotherapy in HNCs patients is a reliable method for ruling out residual/recurrent nodal disease and obviates the need for therapeutic intervention. However, further standardization of the PET technique is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
250P - Impact of adjuvant chemo(radio)therapy in stage I/II testicular seminoma
Presenter: Mahmoud Eleisawy
Session: Poster Display
Resources:
Abstract
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract